Resistance to Targeted Therapies in Lymphomas
This volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical respo
- PDF / 5,283,302 Bytes
- 220 Pages / 439.42 x 683.15 pts Page_size
- 21 Downloads / 215 Views
Ana C. Xavier Mitchell S. Cairo Editors
Resistance to Targeted Therapies in Lymphomas
Resistance to Targeted Anti-Cancer Therapeutics Volume 21
Series Editor Benjamin Bonavida Los Angeles, CA, USA
More information about this series at http://www.springer.com/series/11727
Ana C. Xavier • Mitchell S. Cairo Editors
Resistance to Targeted Therapies in Lymphomas
Editors Ana C. Xavier Division of Hematology/Oncology Department of Pediatrics University of Alabama at Birmingham Children’s Hospital of Alabama Birmingham, AL, USA
Mitchell S. Cairo Departments of Pediatrics, Medicine, Pathology, Microbiology and Immunology, Cell Biology and Anatomy New York Medical College Valhalla, NY, USA
ISSN 2196-5501 ISSN 2196-551X (electronic) Resistance to Targeted Anti-Cancer Therapeutics ISBN 978-3-030-24423-1 ISBN 978-3-030-24424-8 (eBook) https://doi.org/10.1007/978-3-030-24424-8 © Springer Nature Switzerland AG 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Switzerland AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Preface
Lymphomas are a complex group of hematological malignancies that have distinctive etiology, epidemiology, clinical behavior, and response to therapy. For decades, multidrug chemotherapy and/or radiation therapy constituted sole backbones to treat those patients. However, the development of resistance to conventional therapy, due to a multitude of genetic, epigenetic, metabolic mechanisms among others, has contributed to hinder the therapeutic success in a significant proportion of patients. More recently, remarkable advancements in the lymphoma field, with better understanding of lymphoma cell biology and its microenvironment, have contributed to the development of biologic or “targeted” agents and consequent rapid exp
Data Loading...
